00013.HK
HUTCHMED (China) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 22.54
+3.02%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−58.5x
Market Cap
HKD 19.35B
MomentumView details →
1D Return
+3.02%
YTD Return
+9.31%
RSI (14)
73.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−58.5x
Market Cap
HKD 19.35B
RSI (14)
73.6
MomentumView details →
1D Return
+3.02%
YTD Return
+9.31%
Similar companies
Latest newsMore news →
Hutchison China MediTech and GlaxoSmithKline reached a licensing agreement for a KRAS-EGFR antibody-drug conjugate cancer drug.2d agoChina's National Medical Products Administration approved HUTCHMED's ATLED (fanregratinib) for the treatment of patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.8d agoHUTCHMED announced that its registrational Phase 2 trial of Fanregratinib met the primary endpoint in bile duct cancer, and its New Drug Application for the drug was accepted for review and granted priority.72d ago